drugset
drugset / Trial / NCT06084104

DZD9008 PK Study in Hepatic Impairment Subjects

NCT06084104 ↗

Phase 1 Completed 17 enrolled Dizal Pharmaceuticals PPD Development, LP · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function

Timeline

Start
2023-10-17
Primary completion
2024-06-12
Completion
2024-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunvozertinib Small molecule 200 mg Oral

Indications

No indication recorded.